相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Claire Harrison received the European Hematology Association (EHA) 2026 Lifetime Achievement Award for her pioneering work in myeloproliferative neoplasms (MPN). - The landmark COMFORT-II Phase 3 trial established JAK inhibitors as the first effective therapy for myelofibrosis, rapidly improving symptoms, shrinking spleens, and extending survival. - Emerging targeted therapies, including a novel Type II JAK inhibitor, the anti-CALR monoclonal antibody INCA033989, and the SENTRY combination of selinexor plus ruxolitinib, signal a shift toward disease modification. - Harrison envisions the next decade moving MPN care from symptom control toward cure or minimal disease, with patients achieving good quality of life.
- Ropeginterferon alfa-2b achieved a 42.9% sustained response rate compared to 6.0% with anagrelide in patients with essential thrombocythemia resistant or intolerant to hydroxyurea. - The drug demonstrated superior molecular responses with 27.8% partial and 2.8% complete molecular responses, while anagrelide showed no molecular responses. - Ropeginterferon alfa-2b significantly reduced thrombotic events to 1.1% versus 8.8% with anagrelide and showed better safety profile with fewer treatment discontinuations. - The SURPASS-ET trial results support ropeginterferon as a promising disease-modifying therapy for high-risk essential thrombocythemia patients.
- Patients with relapsed/refractory multiple myeloma from lower socioeconomic backgrounds report significantly worse quality of life and higher prevalence of clinically important symptoms that limit daily activities. - Multiple myeloma mortality rates remain nearly twice as high among patients from households earning less than $40,000 annually compared to those earning over $120,000, with rural patients also experiencing higher mortality rates. - Chronic kidney disease emerges as a significant comorbidity that increases risk of high-risk multiple myeloma diagnosis, advanced disease stage, and mortality in affected patients.
